Melola Discovery

← Melola Discovery

Open access Journal SINTA 1

Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial

ACTA MEDICA INDONESIANA · Vol. 58 No. 3 (2026)

ISSN
2338-2732, 0125-9326
Published
2026-10-07
Publisher
The Indonesian Society of Internal Medicine
Language
eng
License
creativecommons.org/licenses/by/4.0

Abstract

Background: Patients with chronic kidney disease undergoing hemodialysis are at risk of hepatitis C virus exposure due to nosocomial transmission and the duration of hemodialysis. The treatment for hepatitis C in patients with chronic kidney disease undergoing hemodialysis is oral direct-acting antiviral (DAA) therapy, which works directly as an antiviral. Currently, the DAA considered safe for use in patients with chronic kidney disease is grazoprevir/elbasvir. However, this DAA is expensive and effective in patients with genotypes 1 and 4. Recent studies have shown that sofosbuvir-based regimens are safe. Therefore, this study aimed to compare the efficacy and safety of sofosbuvir/daclatasvir with grazoprevir/elbasvir in patients with chronic hepatitis C undergoing hemodialysis. Methods: We conducted a multicenter, single-blind, randomized clinical trial that included 120 treatment-naïve, HCV-infected hemodialysis patients. We randomized only participants with fibrosis < F4. Patients with cirrhosis (F4) were assigned to sofosbuvir/daclatasvir per guideline-based contraindications for grazoprevir/elbasvir. Participants received sofosbuvir/daclatasvir or grazoprevir/elbasvir. The primary endpoints were sustained virologic response at week 12 (SVR12) and treatment-related adverse events. Statistical comparisons were conducted using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Results: 120 patients completed the study, with no dropouts or missing SVR12 data. All patients (100%) achieved SVR12 in both treatment groups. Sofosbuvir/daclatasvir and grazoprevir/elbasvir achieved 100% SVR at 12 weeks, with good safety and no adverse events in 98.3% of patients. Conclusion: Both sofosbuvir/daclatasvir and grazoprevir/elbasvir are highly effective and safe for treating hepatitis C in patients undergoing hemodialysis. Sofosbuvir/daclatasvir offers broader applicability across all fibrosis stages and genotypes, with substantially lower treatment costs.

Keywords

Collaboration network of the authors

40 authors · 239 co-authorship links · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • University of Indonesia
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Juferdy KurniawanAffiliation unknown9
Irsan HasanAffiliation unknown7
Rino Alvani GaniAffiliation unknown6
Hamzah ShatriAffiliation unknown5
Chyntia Olivia Maurine JasirwanAffiliation unknown5
Alvina WidhaniAffiliation unknown3
Ika Prasetya WijayaAffiliation unknown3
Cosmas Rinaldi A LesmanaAffiliation unknown3
Kemal Fariz KalistaAffiliation unknown3
Ikhwan RinaldiAffiliation unknown3
Evy YunihastutiAffiliation unknown3
Ni Made HustriniAffiliation unknown3
Marcellus SimadibrataAffiliation unknown3
Cosmas Rinaldi Adithya LesmanaAffiliation unknown3
Eka Surya NugrahaAffiliation unknown2
Siti Aminah AbdurachmanAffiliation unknown2
Kuntjoro HarimurtiAffiliation unknown2
Aida LydiaAffiliation unknown2
Suhardjono SuhardjonoAffiliation unknown2
Em YunirUniversity of Indonesia2
Maruhum Bonar H MarbunAffiliation unknown2
Maruhum Bonar Hasiholan MarbunAffiliation unknown2
Dadang MakmunAffiliation unknown2
Murdani AbdullahAffiliation unknown2
Adityo SusiloAffiliation unknown2
Nenny AgustantiAffiliation unknown2
Gita ApriliciaAffiliation unknown2
Sally Aman NasutionAffiliation unknown2

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, first harvested 8 Nov 2026, last seen 16 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis:  A Multicentre, Single-Blind, Randomised Controlled Trial</dc:title>
	<dc:creator>Sulaiman, Andri Sanityoso</dc:creator>
	<dc:creator>Nugroho, Pringgodigdo</dc:creator>
	<dc:creator>Bestari, Muhammad Begawan</dc:creator>
	<dc:creator>Afiatin, Afiatin</dc:creator>
	<dc:creator>Akil, Fardhah</dc:creator>
	<dc:creator>Albaar, Akhyar</dc:creator>
	<dc:creator>Purnomo, Hery Djagat</dc:creator>
	<dc:creator>Lestari, Dwi</dc:creator>
	<dc:creator>Pramana, Triyanta Yuli</dc:creator>
	<dc:creator>Susanto, Agung</dc:creator>
	<dc:creator>Rachmani, Desti</dc:creator>
	<dc:creator>Khek-Yu, Lawrence Ho </dc:creator>
	<dc:subject xml:lang="en-US">Hepatitis C</dc:subject>
	<dc:subject xml:lang="en-US">chronic</dc:subject>
	<dc:subject xml:lang="en-US">Chronic Kidney Disease</dc:subject>
	<dc:subject xml:lang="en-US">Hemodialysis</dc:subject>
	<dc:subject xml:lang="en-US">sofosbuvir</dc:subject>
	<dc:subject xml:lang="en-US">daclatasvir</dc:subject>
	<dc:subject xml:lang="en-US">grazoprevir</dc:subject>
	<dc:subject xml:lang="en-US">elbasvir</dc:subject>
	<dc:description xml:lang="en-US">Background: Patients with chronic kidney disease undergoing hemodialysis are at risk of hepatitis C virus exposure due to nosocomial transmission and the duration of hemodialysis. The treatment for hepatitis C in patients with chronic kidney disease undergoing hemodialysis is oral direct-acting antiviral (DAA) therapy, which works directly as an antiviral. Currently, the DAA considered safe for use in patients with chronic kidney disease is grazoprevir/elbasvir. However, this DAA is expensive and effective in patients with genotypes 1 and 4. Recent studies have shown that sofosbuvir-based regimens are safe. Therefore, this study aimed to compare the efficacy and safety of sofosbuvir/daclatasvir with grazoprevir/elbasvir in patients with chronic hepatitis C undergoing hemodialysis. Methods: We conducted a multicenter, single-blind, randomized clinical trial that included 120 treatment-naïve, HCV-infected hemodialysis patients. We randomized only participants with fibrosis &amp;lt; F4. Patients with cirrhosis (F4) were assigned to sofosbuvir/daclatasvir per guideline-based contraindications for grazoprevir/elbasvir. Participants received sofosbuvir/daclatasvir or grazoprevir/elbasvir. The primary endpoints were sustained virologic response at week 12 (SVR12) and treatment-related adverse events. Statistical comparisons were conducted using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Results: 120 patients completed the study, with no dropouts or missing SVR12 data. All patients (100%) achieved SVR12 in both treatment groups. Sofosbuvir/daclatasvir and grazoprevir/elbasvir achieved 100% SVR at 12 weeks, with good safety and no adverse events in 98.3% of patients. Conclusion: Both sofosbuvir/daclatasvir and grazoprevir/elbasvir are highly effective and safe for treating hepatitis C in patients undergoing hemodialysis. Sofosbuvir/daclatasvir offers broader applicability across all fibrosis stages and genotypes, with substantially lower treatment costs.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2026-10-07</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/3295</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 58 No. 3 (2026): Acta Medica Indonesiana; 415</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/3295/900</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2026 Andri Sanityoso Sulaiman, Pringgodigdo Nugroho, Muhammad Begawan Bestari, Afiatin Afiatin, Fardhah Akil, Akhyar Albaar, Hery Djagat Purnomo, Dwi Lestari, Triyanta Yuli Pramana, Agung Susanto, Desti Rachmani, Lawrence Ho  Khek-Yu</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>